MGMT and neoplasm: Though researchers had found that isocitrate dehydrogenase-1 (IDH1) mutation, codeletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p/19q), and O-6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation were identified as prognostic markers and therapeutic targets involved in tumor classification and progression in recent years, despite this, the OS rate does not appear to have improved significantly [3–5].